Navigation Links
SuperNova Diagnostics® to Present at Biotech Showcase™ 2011 During J.P. Morgan Healthcare Conference January 10-13
Date:1/5/2011

WASHINGTON, LONDON and HONG KONG, Jan. 5, 2011 /PRNewswire/ -- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, announced today that Neil J. Campbell, president and CEO, will present at Biotech Showcase 2011 in conjunction with the J.P. Morgan Healthcare Conference in San Francisco, CA.  

Mr. Campbell's presentation will be given at the Parc 55 Wyndham Hotel on Wednesday, January 12, 2011 at 3:30 p.m. PST.  "We are delighted to be presenting at a renowned conference such as Biotech Showcase," said Mr. Campbell.  "Biotech Showcase and the J.P. Morgan Healthcare Conference provide a unique opportunity to present to a diverse group of first-class investors and executives interested in medical and industrial diagnostics."

AmpCrystal®, SuperNova Diagnostics' lead technology and its multiple product formats, allows for minimally trained individuals (advanced CLIA-waived) to test for a wide range of protein analytes and can detect directly un-amplified DNA in humans, animals or environmental samples.  

Time-to-result has been shown in prototypes to be reduced to minutes on the spot versus the hours or days required when sending samples to a central laboratory or processing in regional satellite laboratories.  With three integrated capabilities (sample collector/processor, analytical disposable, and the readout device), the technology is simpler, more robust, faster and significantly less expensive than existing POC systems.

Significant advantages of AmpCrystals are direct detection of samples, simplification of product designs, ability to lower costs of delivery and broaden range of assay formats from the central laboratory.

About SuperNova Diagnostics®, Inc.SuperNova® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications.  A powerful proprietary nanochemistry, AmpCrystal®, can delivery novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements.  SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNova® - Putting the Laboratory in the Palm of Your Hand®.

For additional information, please visit www.supernovadiagnostics.com.Media Contacts:Tiberend Strategic Advisors, Inc.(212) 827-0020Tamara Bright, tbright@tiberend.comorFarrell Denby, fdenby@tiberend.com
'/>"/>

SOURCE SuperNova Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
2. InterMune to Present at J.P. Morgan Healthcare Conference
3. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
4. Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
5. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
6. PDL BioPharma to Present at the 29th Annual JP Morgan Healthcare Conference
7. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
8. Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12
9. HeartWare to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
Breaking Medicine News(10 mins):